Status:
COMPLETED
A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)
Lead Sponsor:
CSL Behring
Conditions:
Von Willebrand Disease
Eligibility:
All Genders
Brief Summary
As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective, multi-center structure...
Eligibility Criteria
Inclusion
- Male or female patients of any age;
- Patients who are suffering with von Willebrand disease previously treated with Humate-P®;
- Patients who are able to communicate well with the Investigator and his/her representatives;
- Patients who are able and agreeing to comply with all study requirements;
- Patients who have provided written signed and dated informed consent prior to any study procedures being performed.
Exclusion
- Patients who have received any investigational drug ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00701545
Start Date
February 1 2008
End Date
April 1 2009
Last Update
February 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto, Canada